(Q35093636)

6 August 2017

1 reference

title

Adalimumab - a new TNF-alpha antibody for treatment of inflammatory joint disease (English)

1 reference

6 August 2017

0 references

2

Josef S Smolen

1 reference

6 August 2017

Klaus P Machold

1

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

Expert Opinion on Biological Therapy

6 August 2017

published in

1 reference

6 August 2017

volume

3

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

351-360

1 reference

TNF alpha--a pivotal role in rheumatoid arthritis?

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.351

Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.351

Influence of cyclosporin A on radiological progression in early rheumatoid arthritis patients: a 42-month prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.351

Cytokine profile in chronic cardiac failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.351

Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.351

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.351

Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.351

Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.351

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.351

Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.351

Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.351

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.351

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.351

Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.351

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.351

Controlled trial of hydroxychloroquine and D-penicillamine singly and in combination in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.351

Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.351

Combination therapy with methotrexate and chloroquine in rheumatoid arthritis. A multicenter randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.351

COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.351

Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.351

Combined suppressive drug treatment in severe refractory rheumatoid disease: an analysis of the relative effects of parenteral methylprednisolone, cyclophosphamide, and sodium aurothiomalate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.351

The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.351

21 January 2018

Identifiers

DOI

10.1517/14712598.3.2.351

1 reference

6 August 2017

1 reference